U.S. Secretary of State Hillary Clinton on Tuesday visited officials in South Africa and discussed the response to HIV/AIDS, the Associated Press/Huffington Post reports. Speaking with Foreign Minister Maite Nkoana-Mashabane “in the second cabinet-level strategic dialogue between the two nations,” Clinton said “that global efforts to stop the virus ‘have saved hundreds of thousands of lives,'” the news service writes. “In South Africa, 5.7 million people — 17.8 percent of the population — have tested positive for HIV,” and PEPFAR “has spent $3.2 billion on antiretroviral drugs and HIV prevention programs in [the country] since 2004,” according to the AP.
Programs, Funding & Financing
Inter Press Service reports on the successful efforts of Tanzania’s Kigoma Region “to train assistant medical officers to conduct life-saving c-sections at its rural health centers,” allowing pregnant women with complications to deliver at more local facilities instead of having to travel to regional or district hospitals. Tanzania’s maternal mortality rate is high, at 578 deaths for every 100,000 live births, IPS notes. “[A]t one point the Kigoma Region had the highest rate in the country, at 933 per 100,000 live births in the early 1980s,” but “maternal mortality in this region [now] is considered to be lower than in the rest of the country,” according to the news service.
Science looks back at the XIX International AIDS Conference (AIDS 2012), which ended last week in Washington, D.C., writing, “The battle against HIV is having more success than ever. … But several presentations made clear that a gulf separates aspirations from reality when it comes to ‘ending AIDS,’ which [Secretary of State Hillary] Clinton and many other prominent speakers at the conference emphasized was now possible.” Though more people are on antiretrovirals (ARVs) now than ever, low- and middle-income countries are spending more on HIV/AIDS, and “attempts to find a cure — long viewed as a fantasy — now lead the scientific agenda,” most “of the 34 million HIV-infected people in the world do not take ARVs, many receiving treatment have trouble staying on the medication, … new infection rates continue to climb in key populations,” “[n]o AIDS vaccine is on the horizon,” and “funding shortfalls loom for global programs,” Science writes, quoting several speakers at the conference and providing more detail on the successes and challenges in the response against HIV/AIDS (Cohen, 8/3).
In a series of “News Focus” articles in Science, the magazine examines the global effort to eradicate polio. One article examines the Global Polio Eradication Initiative (GPEI) — a partnership of the WHO, Rotary International, UNICEF, the CDC, and the Bill & Melinda Gates Foundation — and recent reports on the program by an Independent Monitoring Board (IMB), “an oversight body” that provides feedback and guidance. A second and third article look at efforts to vaccinate children against polio in Pakistan, which “is the perfect case study for why it is so hard to eradicate poliovirus from its last few strongholds — and what it might take to pull it off.” The WHO’s Chris Maher “and others attribute the explosion of cases last year to a perfect storm of all the problems that are Pakistan: poverty and illiteracy; a health system in tatters; ethnic and sectarian violence; a government struggling to deal with corruption and dysfunction; huge population movements; and, especially since 9/11, rising extremism and anti-Western views — not to mention the natural attrition that accompanies any program that has dragged on for so long,” according to Science (Roberts, 8/3).
“The United States announced Thursday it would hike its humanitarian aid to Syria, adding another $12 million to provide food, water, medicine and other necessities for battered and displaced people” affected by violence in the Syrian conflict, the Los Angeles Times blog “World Now” reports. “The increase approved by the Obama administration brings American humanitarian assistance in Syria to more than $76 million, including $27.5 million to the World Food Programme [WFP], roughly $18 million for the United Nations refugee agency and the rest split among other U.N. funds and non-profit groups,” the blog writes (Alpert, 8/2).
Gilead Sciences Signs Deals With 3 Indian Pharmaceutical Companies To Promote Low-Cost HIV Drugs In Developing Countries
Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. “to promote access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries,” the Wall Street Journal reports (Stevenson, 8/2). Gilead signed deals with the three Indian companies “to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries,” Reuters reports, noting that under the deals, Gilead “will provide technology and funding to help reduce manufacturing costs of the drug, the companies said” (Kuber, 8/2).
PEPFAR on Wednesday “announced awards for a $60 million initiative, with potential for additional funding in year three, to support implementation science research and the evaluation of programs established under PEPFAR,” according to a U.S. State Department media note. “These evaluations, funded through collaboration with the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the U.S. Agency for International Development (USAID), will contribute to the evidence base for HIV programs and maximize the impact of its investments in programs around the world. Data gathered will help partner countries to strengthen their efforts to prevent new HIV infections and save lives,” the media note states, adding, “More than 35 evaluations in over 12 countries will be funded in 2012” (8/1).
On the first stop of a 10-day tour of Africa, Secretary of State Hillary Clinton stopped at the Phillipe Maguilen Senghor Health Center in Dakar, Senegal, where Awa Marie Coll-Seck, the country’s minister of health, “explained to Secretary Clinton how these operational centers dramatically improve maternal and child health,” according to a post in USAID’s “IMPACTblog.” Coll-Seck “also noted that USAID-supported distribution of insecticide impregnated mosquito nets across the country had drastically reduced the incidence of malaria,” according to the blog, which adds that Clinton “was pleased to hear that the United States is playing a key role in helping meet one of its biggest challenges: decentralizing services so they are available at the village level throughout the country.” In an address several hours later, “Clinton invoked the Senghor center … saying she was highly impressed by the integrated nature of the facility” and that “[i]t was a successful model she hoped could be duplicated throughout Senegal and the entire West African region” (Taylor, 8/1).
In this post on the Center for Global Development’s (CGD) “Global Health Policy” blog, CGD’s Victoria Fan, Rachel Silverman, and Amanda Glassman examine “the preliminary report [.pdf] on the pilot of PEPFAR’s Expenditure Analysis Initiative, an important and exciting move by PEPFAR towards evidence-based decision making and greater transparency.” Expenditure analysis (EA) “provides an account of where money gets spent and on what,” they continue, adding, “Here’s why it could be a game changer: This seemingly simple tool is essential for realizing huge potential gains in both technical and allocative efficiency, two core components of value for money.” After describing some of the report’s shortcomings, they write that “the report demonstrates the wide range of potential applications for using EA to improve value for money, which is particularly encouraging given PEPFAR’s plans to institutionalize EA into its routine annual reporting” (8/1).
In this post in the Center for Global Development’s (CGD) “Global Health Policy” blog, Amanda Glassman, director of global health policy and a research fellow at the center, reports on the contribution of economists to the global health field, writing, “Economists are not global health’s most popular human resource. … Yet a new view of the contribution of economists to global health is emerging.” She notes, “At the International AIDS Economics Network (IAEN) meeting earlier this month, [U.S. Global AIDS Coordinator] Ambassador Eric Goosby gave a terrific overview of the policy questions that need to be addressed by the field and the role that economists need to play in improving the efficiency and effectiveness of the HIV/AIDS response,” and provides a number of quotes from his address (8/1).